Kevin M. Klemz - Sep 17, 2024 Form 4 Insider Report for Silk Road Medical Inc (SILK)

Role
EVP/Chief Legal Officer/Sec.
Signature
/s/ Mhairi Jones, by power of attorney
Stock symbol
SILK
Transactions as of
Sep 17, 2024
Transactions value $
$0
Form type
4
Date filed
9/18/2024, 08:31 PM
Previous filing
Aug 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SILK Common Stock Disposed to Issuer -163K -100% 0 Sep 17, 2024 Direct F1, F2, F3
transaction SILK Common Stock Award $0 +29.1K $0.00 29.1K Sep 17, 2024 Direct F4
transaction SILK Common Stock Disposed to Issuer -29.1K -100% 0 Sep 17, 2024 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Kevin M. Klemz is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Of the reported shares, 154,066 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
F2 Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.
F3 Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
F4 Immediately prior to the effective time of the merger, certain RSUs subject to the achievement of performance-based criteria, or PSUs, were deemed achieved and certified by the Issuer's compensation committee.
F5 Pursuant to the Merger Agreement, each PSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the PSUs, less applicable taxes and authorized deductions.